Catalent (NYSE:CTLT) Trading Down 4.1% on Analyst Downgrade
Catalent (NYSE:CTLT) Trading Down 4.1% on Analyst Downgrade
Catalent, Inc. (NYSE:CTLT – Get Rating)'s stock price was down 4.1% on Tuesday after Barclays lowered their price target on the stock from $62.00 to $58.00. Barclays currently has an overweight rating on the stock. Catalent traded as low as $50.36 and last traded at $50.44. Approximately 154,255 shares were traded during trading, a decline of 94% from the average daily volume of 2,555,757 shares. The stock had previously closed at $52.59.
週二,在巴克萊將Catalent的目標股價從62.00美元下調至58.00美元后,Catalent的股價下跌了4.1%。巴克萊目前對該股的評級為增持。Catalent的交易價格最低為50.36美元,最新報50.44美元。盤中成交量約為154,255股,較日均成交量2,555,757股下降了94%。該股此前收盤報52.59美元。
Other equities research analysts have also recently issued research reports about the company. Morgan Stanley dropped their price objective on Catalent from $120.00 to $81.00 and set an "overweight" rating on the stock in a research note on Thursday, November 3rd. Bank of America cut Catalent from a "buy" rating to a "neutral" rating and lowered their price objective for the stock from $125.00 to $60.00 in a research report on Wednesday, November 2nd. Argus lowered Catalent from a "buy" rating to a "hold" rating in a report on Monday, November 7th. Royal Bank of Canada reduced their target price on Catalent from $125.00 to $73.00 and set an "outperform" rating on the stock in a report on Wednesday, November 2nd. Finally, TheStreet lowered Catalent from a "b-" rating to a "c+" rating in a research note on Friday, October 28th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Hold" and an average price target of $92.40.
其他股票研究分析師最近也發佈了關於該公司的研究報告。11月3日,摩根士丹利在一份研究報告中將卡特倫特股票的目標價從120.00美元下調至81美元,並對該股設定了“增持”評級。11月2日,美國銀行在一份研究報告中將Catalent的評級從買入下調至中性,並將該股的目標價從125.00美元下調至60美元。Argus在11月7日週一的一份報告中將Catalent的評級從買入下調至持有。加拿大皇家銀行在11月2日週三的一份報告中將其對卡特倫特的目標價從125.00美元下調至73.0美元,並對該股設定了“跑贏大盤”的評級.最後,華爾街在10月28日星期五的一份研究報告中將Catalent的評級從B-下調至C+。一位分析師對該股的評級為賣出,三位分析師給出了持有評級,五位分析師給出了買入評級。根據MarketBeat.com的數據,該股的平均評級為持有,平均目標價為92.40美元。
Insider Buying and Selling at Catalent
Catalent的內幕買賣
In related news, SVP Michael J. Grippo sold 2,451 shares of the business's stock in a transaction on Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the sale, the senior vice president now directly owns 17,792 shares in the company, valued at approximately $1,171,247.36. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Michael J. Grippo sold 2,451 shares of the business's stock in a transaction dated Monday, October 31st. The stock was sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the transaction, the senior vice president now directly owns 17,792 shares in the company, valued at $1,171,247.36. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Manja Boerman sold 780 shares of the company's stock in a transaction dated Monday, December 5th. The stock was sold at an average price of $51.70, for a total value of $40,326.00. Following the completion of the transaction, the insider now owns 15,860 shares of the company's stock, valued at $819,962. The disclosure for this sale can be found here. Corporate insiders own 0.58% of the company's stock.
在相關新聞中,高級副總裁邁克爾·J·格里波在10月31日星期一的一次交易中出售了2451股該公司的股票。該股以65.83美元的平均價格出售,總成交金額為161,349.33美元。出售股份後,高級副總裁現在直接持有該公司17,792股股份,價值約1,171,247.36美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過美國證券交易委員會網站。在相關新聞中,高級副總裁邁克爾·J·格里波在一筆日期為10月31日星期一的交易中出售了2451股該公司的股票。該股以65.83美元的平均價格出售,總成交金額為161,349.33美元。交易完成後,高級副總裁現在直接擁有該公司17,792股,價值1,171,247.36美元。這筆交易是在提交給美國證券交易委員會的一份文件中披露的,該文件可通過這個環節。此外,內部人士Manja Boerman在12月5日星期一的交易中出售了780股該公司股票。這隻股票的平均售價為51.70美元,總價值為40,326.00美元。交易完成後,這位內部人士現在擁有15,860股該公司股票,價值819,962美元。關於這次銷售的披露可以找到這裏。企業內部人士持有該公司0.58%的股份。
Institutional Investors Weigh In On Catalent
機構投資者看好Catalent
Catalent Price Performance
催化劑的性價比
The business has a 50-day simple moving average of $46.22 and a 200 day simple moving average of $72.04. The firm has a market cap of $8.92 billion, a P/E ratio of 21.18, a price-to-earnings-growth ratio of 3.41 and a beta of 1.24. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86.
該業務的50日簡單移動均線切入位為46.22美元,200日簡單移動均線切入位為72.04美元。該公司市值89.2億美元,市盈率21.18倍,市盈率3.41倍,貝塔係數1.24。該公司的負債權益比率為0.87,速動比率為2.08,流動比率為2.86。
Catalent (NYSE:CTLT – Get Rating) last released its quarterly earnings results on Tuesday, November 1st. The company reported $0.25 EPS for the quarter, missing analysts' consensus estimates of $0.49 by ($0.24). Catalent had a net margin of 8.83% and a return on equity of 12.55%. The business had revenue of $1.02 billion for the quarter, compared to the consensus estimate of $1.06 billion. On average, analysts anticipate that Catalent, Inc. will post 2.93 earnings per share for the current fiscal year.
Catalent(NYSE:CTLT-GET Rating)最近一次發佈季度收益報告是在11月1日(星期二)。該公司公佈本季度每股收益為0.25美元,低於分析師普遍預期的0.49美元(0.24美元)。Catalent的淨利潤率為8.83%,股本回報率為12.55%。該業務本季度營收為10.2億美元,而市場普遍預期為10.6億美元。分析師平均預計,Catalent,Inc.本財年每股收益將達到2.93美元。
About Catalent
關於Catalent
(Get Rating)
(獲取評級)
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
Catalent公司及其子公司在全球範圍內開發和製造藥物、基於蛋白質的生物製劑、細胞和基因療法以及消費者保健產品的解決方案。軟凝膠和口腔技術部門提供用於一系列客户產品的軟膠囊的配方、開發和製造服務,如處方藥、非處方藥、膳食補充劑、單位劑量化粧品和動物保健藥物製劑。
Further Reading
進一步閲讀
- Get a free copy of the StockNews.com research report on Catalent (CTLT)
- High-Yield, Deep-Value Verizon Puts In A Bottom
- Should You Bet Against The Nasdaq 100 With This Inverse ETF?
- Can Coty Stock Emerge in 2023 With Upside
- Insiders Buy Archer Aviation, Is This Stock About To Take Off?
- Intuit Is About To Make a Move, But Which Way?
- 免費獲取StockNews.com關於Catalent的研究報告(CTLT)
- 高收益、高價值的Verizon陷入谷底
- 你應該用這隻反向ETF做空納斯達克100指數嗎?
- 科蒂股票能否在2023年出現上行
- 業內人士買入阿徹航空,這隻股票要起飛了嗎?
- Intuit即將採取行動,但走哪條路呢?
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.
接受《Catalent Daily》的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對Catalent和相關公司的最新新聞和分析師評級的每日簡要摘要。